CUPERTINO, Calif., May 17 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that Voyager Pharmaceutical has provided its
shareholders with an update on its truncated Phase 3 clinical trial for
Memryte, an investigational drug for the treatment of Alzheimer’s disease.
Voyager has informed its shareholders that they have observed positive outcome
trends among women, but no positive effect among men. DURECT has not
independently verified the analysis performed or conclusions of Voyager.
Based on these results, Voyager has stated that it intends to focus its
efforts on developing Memryte for the treatment of Alzheimer’s disease in
women and on seeking a potential partner for the program.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company
developing pharmaceutical systems based on its proprietary drug delivery
platform technologies. The Company currently has a number of late-stage
pharmaceutical products in development addressing large markets in pain
management, with a number of research programs underway targeting chronic
disease and other therapeutic areas. For more information, please visit
www.www.durect.com.
Forward-Looking Statement
The statements in this press release regarding Memryte, its potential
performance and attributes, future development plans for Memryte and efforts
by Voyager to seek a partner for the program are forward-looking statements
involving risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Voyager’s abilities to attract
and reach business terms with a partner for the Memryte program, design,
enroll, conduct and complete clinical trials, obtain successful results from
such clinical trials, complete the design, development, and manufacturing
process development of Memryte, obtain regulatory and manufacturing approvals
from regulatory agencies, and manufacture and commercialize Memryte, as well
as marketplace acceptance of Memryte. Further information regarding these and
other risks is included in DURECT’s Form 10-Q dated May 9, 2007 under the
heading “Risk Factors.”
NOTE: Memryte is under development and has not been submitted or approved
for commercialization by the US Food and Drug Administration or other health
authorities.
SOURCE DURECT Corporation
05/17/2007
CONTACT: Jeremiah Hall, Senior Vice President of Feinstein Kean
Healthcare, +1-415-677-2700, or jeremiah.hall@fkhealth.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840
Web site: http://www.www.durect.com
(DRRX)